February 2013 | Oncology & Biotech News

EGFR Mutation Not a Prognostic Factor for NSCLC

February 28, 2013

Although the presence of an EGFR mutation is a predictive marker for response to EGFR tyrosine kinase inhibitor therapy in patients with non-small cell lung cancer, the mutation is not a prognostic factor.

Alterations in CYP2D6 Enzyme Affect Efficacy of Tamoxifen

February 21, 2013

Genetic or drug-induced alterations of the enzyme CYP2D6 that result in reduced metabolism of tamoxifen are associated with a higher risk of recurrence and death in women with ER–positive breast cancer who receive the drug.